Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 11 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $39.1M
- Insider buysLast 90 days, $807.5K in total
- 11
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 33
- 13F valueReported value at the end of Q2 2026
- $8.74M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- –
- No comparable prior period
- Net income, FY2026
- -$7.79M
- No comparable prior period
- Free cash flow, FY2026
- –
- No comparable prior period
- Revenue, Q1 FY2027
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.67M
- Shares sold short
- Change
- −16.1K
- −1.0% vs. previous
- Days to cover
- 12.33
- At average daily volume
Superinvestors holding GRCE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding GRCE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Grace Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)9:05 PM ET | Nov 3-5 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +18.4K | $1.79 | +$33.0K | +0.6%3.05M after | 3 lots |
| Oct 26, 2026 (view filing)6:06 PM ET | Oct 22-26 | 4 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +87.8K | $1.81 | +$158.6K | +3.0%3.04M after | 2 lots |
| Oct 21, 2026 (view filing)6:06 PM ET | Oct 19 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +4.26K | $1.88 | +$8.00K | +0.1%2.95M after | |
| Oct 16, 2026 (view filing)8:42 PM ET | Oct 14-16 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +71.1K | $1.92 | +$136.2K | +2.5%2.94M after | 3 lots |
| Oct 13, 2026 (view filing)5:45 PM ET | Oct 8-12 | 5 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +14.6K | $2.03 | +$29.7K | +0.5%2.87M after | 3 lots |
| Oct 5, 2026 (view filing)6:46 PM ET | Oct 1-5 | 4 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +60.5K | $2.05 | +$123.8K | +2.2%2.86M after | 3 lots |
| Oct 1, 2026 (view filing)4:30 PM ET | Sep 29 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +7.85K | $2.09 | +$16.4K | +0.3%2.80M after | |
| Oct 1, 2026 (view filing)4:05 PM ET | Sep 21-23 | 10 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +15.1K | $2.10 | +$31.7K | +0.5%2.79M after | Amended2 lots |
| Sep 10, 2026 (view filing)4:05 PM ET | Sep 8-9 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +15.2K | $2.09 | +$31.9K | +0.6%2.78M after | 2 lots |
| Sep 10, 2026 (view filing)7:30 AM ET | Sep 9 | 1 day | Kohli PrashantChief Executive Officer | PPurchase | +100.0K | $2.14 | +$214.0K | +468.2%121.4K after |
Top 10 13F holders, Q2 2026
See all 33 holdersThe largest institutional positions in Grace Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cerity Partners LLC | 849,055 | $1.93M | 0.00% | 00.0% | Unchanged |
| Eversept Partners, LP | 772,900 | $1.75M | 0.10% | +16,300+2.2% | Added |
| Bank of America Corp | 494,698 | $1.12M | 0.00% | −250.0% | Reduced |
| Vanguard Capital Management LLC | 411,714 | $934.6K | 0.00% | +10,058+2.5% | Added |
| Citadel Advisors LLC | 349,740 | $793.9K | 0.00% | +250,998+254.2% | Added |
| Maven Securities LTD | 200,000 | $454.0K | 0.03% | +200,000 | New |
| Birchview Capital, LP | 120,000 | $272.4K | 0.13% | +70,000+140.0% | Added |
| Cantor Fitzgerald, L. P. | 100,000 | $227.0K | 0.00% | +100,000 | New |
| Two Sigma Investments, LP | 96,890 | $219.9K | 0.00% | +96,890 | New |
| Jane Street Group, LLC | 89,442 | $203.0K | 0.00% | −77,655−46.5% | Reduced |
Holders of 5% or more of GRCE
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Grace Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 13G | 13.07%2.75M shares | New | Aug 7, 20261 filing | Aug 7, 2026 | SEC |
| ADAR1 Capital Management, LLC | 13G/A | 9.90%1.81M shares | 0.00 ppfrom 9.90% | Jul 10, 20247 filings | Aug 14, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G/A | 6.75%1.18M shares | −3.24 ppfrom 9.99% | May 15, 20254 filings | Aug 14, 2026 | SEC |